Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.
TipRanks on MSN19h
Lantheus Holdings Inc. Reports Strong Growth and Strategic MovesLantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results topping the market’s revenue ...
Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...
Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...
LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...
Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...
In trading on Wednesday, shares of Lantheus Holdings Inc (Symbol: LNTH) crossed above their 200 day moving average of $94.93, changing hands as high as $95.94 per share. Lantheus Holdings Inc ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Argenx Se ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback